News
Sarepta shares slump on reports of third patient death this year
Shares of Sarepta Therapeutics declined 20% in early trading on Friday after media reports that a patient who had received one of its experimental gene therapies has died, deepening investor concern over the use of the company's treatments.
The U.S. Food and Drug Administration will request Sarepta Therapeutics to voluntarily stop all shipments of its gene therapy ...
Key Takeaways Sarepta Therapeutics shares were down nearly 25% early Friday morning.The tumble followed a report that a third ...
While the previous two deaths occurred in patients treated with Elevidys, the most recent patient was receiving one of ...
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...
GlobalData on MSN1d
Sarepta Therapeutics to cut 500 jobs amid restructuringThe company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
These were the most active stocks ahead of Friday's market open: Sarepta Therapeutics Inc.'s stock tumbled 27% after the company said another patient died following gene-therapy treatment, Bloomberg ...
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback